| 1 | pilot | 6,580 |
| 2 | proof-of-concept | 355 |
| 3 | full-scale | 221 |
| 4 | before-after | 170 |
| 5 | first-in-human | 137 |
| 6 | before-and-after | 124 |
| 7 | proof-of-principle | 89 |
| 8 | first-in-man | 88 |
| 9 | follow-on | 61 |
| 10 | vanguard | 34 |
| 11 | hipaa-compliant | 22 |
| 12 | cairo2 | 14 |
| 13 | trials/controlled | 14 |
| 14 | ademex | 13 |
| 15 | food-effect | 13 |
| 16 | gepartrio | 13 |
| 17 | fixed-sample | 12 |
| 18 | single-ascending-dose | 12 |
| 19 | multi-year | 11 |
| 20 | hebe | 10 |
| 21 | euphas | 9 |
| 22 | first-time-in-human | 9 |
| 23 | gissi-af | 9 |
| 24 | guidage | 9 |
| 25 | hoorn | 9 |
| 26 | 38-week | 8 |
| 27 | anglo-danish-dutch | 8 |
| 28 | c-07 | 8 |
| 29 | fruit-juice | 8 |
| 30 | pilot/feasibility | 8 |
| 31 | 2005-01 | 7 |
| 32 | first-in-humans | 7 |
| 33 | group.one | 7 |
| 34 | prefher | 7 |
| 35 | three-pronged | 7 |
| 36 | 60-patient | 6 |
| 37 | bora | 6 |
| 38 | in-human | 6 |
| 39 | multiple-case | 6 |
| 40 | pan-asia | 6 |
| 41 | thalassa | 6 |
| 42 | trial.the | 6 |
| 43 | trialnet | 6 |
| 44 | bfr14 | 5 |
| 45 | capp2 | 5 |
| 46 | helena | 5 |
| 47 | ionia-e | 5 |
| 48 | omegad | 5 |
| 49 | opt-tms | 5 |
| 50 | romio | 5 |
| 51 | trials.one | 5 |
| 52 | 55971 | 4 |
| 53 | artscan | 4 |
| 54 | ce.3 | 4 |
| 55 | consort-compliant | 4 |
| 56 | fiat | 4 |
| 57 | first-in-patient | 4 |
| 58 | geparsixto | 4 |
| 59 | modest-sized | 4 |
| 60 | multi-cohort | 4 |
| 61 | pre-point | 4 |
| 62 | preintervention-postintervention | 4 |
| 63 | shiva | 4 |
| 64 | signal-searching | 4 |
| 65 | ttm-based | 4 |
| 66 | 10981-22023 | 3 |
| 67 | 12-week-long | 3 |
| 68 | 24954 | 3 |
| 69 | 35-week | 3 |
| 70 | a5164 | 3 |
| 71 | anti-atheroma | 3 |
| 72 | chewfree | 3 |
| 73 | co.17 | 3 |
| 74 | european/canadian | 3 |
| 75 | falldem | 3 |
| 76 | firis | 3 |
| 77 | follow-up.one | 3 |
| 78 | husoft | 3 |
| 79 | hypothesis-generation | 3 |
| 80 | meta-analysis.one | 3 |
| 81 | pacome | 3 |
| 82 | pharmacoimaging | 3 |
| 83 | postregistration | 3 |
| 84 | regenerate-ihd | 3 |
| 85 | registry-type | 3 |
| 86 | scorpius | 3 |
| 87 | setting.the | 3 |
| 88 | smile-4 | 3 |
| 89 | -potsdam | 2 |
| 90 | 0501 | 2 |
| 91 | 12174 | 2 |
| 92 | 22881-10882 | 2 |
| 93 | 4-country | 2 |
| 94 | 53-week | 2 |
| 95 | 97-d | 2 |
| 96 | anahydret | 2 |
| 97 | artico | 2 |
| 98 | atmi | 2 |
| 99 | backpassage | 2 |
| 100 | barmer | 2 |
| 101 | calisto | 2 |
| 102 | capp1 | 2 |
| 103 | caress-in-ami | 2 |
| 104 | clinical-experimental | 2 |
| 105 | combi-d | 2 |
| 106 | community-screening | 2 |
| 107 | condition.this | 2 |
| 108 | corea-taxus | 2 |
| 109 | criteria.one | 2 |
| 110 | debiut | 2 |
| 111 | dream3 | 2 |
| 112 | exploratory/descriptive | 2 |
| 113 | glucontrol | 2 |
| 114 | glycogen-depletion | 2 |
| 115 | group-comparison | 2 |
| 116 | implementation-effectiveness | 2 |
| 117 | manikin-based | 2 |
| 118 | mm-bo2005 | 2 |
| 119 | more-care | 2 |
| 120 | multi-rater | 2 |
| 121 | opptimum | 2 |
| 122 | ph2a | 2 |
| 123 | piilr | 2 |
| 124 | process-improvement | 2 |
| 125 | proof-of-mechanism | 2 |
| 126 | review.six | 2 |
| 127 | ricover | 2 |
| 128 | sertraline-controlled | 2 |
| 129 | split-lesion | 2 |
| 130 | strike-through | 2 |
| 131 | syncan | 2 |
| 132 | -asia | 1 |
| 133 | -bio | 1 |
| 134 | -netherlands | 1 |
| 135 | -p1b | 1 |
| 136 | 0104 | 1 |
| 137 | 0110 | 1 |
| 138 | 0110/ml22011 | 1 |
| 139 | 0537 | 1 |
| 140 | 08-06 | 1 |
| 141 | 08062 | 1 |
| 142 | 08983 | 1 |
| 143 | 14,500-patient | 1 |
| 144 | 2000-1 | 1 |
| 145 | 243,400 | 1 |
| 146 | 3,000-patient | 1 |
| 147 | 6-month-treatment | 1 |
| 148 | 62961 | 1 |
| 149 | 70-compound | 1 |
| 150 | 8801 | 1 |
| 151 | 8week | 1 |
| 152 | 9-site | 1 |
| 153 | 94-17 | 1 |
| 154 | 95-06 | 1 |
| 155 | a1chieve® | 1 |
| 156 | actrn12612000889853the | 1 |
| 157 | agents.this | 1 |
| 158 | ago-1 | 1 |
| 159 | alcohol-challenge | 1 |
| 160 | allene-involved | 1 |
| 161 | analytical-descriptive | 1 |
| 162 | anti-dabetic | 1 |
| 163 | b-30 | 1 |
| 164 | bifactorial | 1 |
| 165 | blind-rater | 1 |
| 166 | bronchoscopy.the | 1 |
| 167 | bupropian | 1 |
| 168 | cftr-modulator | 1 |
| 169 | charon | 1 |
| 170 | chemistry-focused | 1 |
| 171 | clinicoepidemiologic | 1 |
| 172 | cll4b | 1 |
| 173 | competence-focused | 1 |
| 174 | criteria-2 | 1 |
| 175 | criteria.this | 1 |
| 176 | criteria.two | 1 |
| 177 | criteriathe | 1 |
| 178 | crossover-randomized | 1 |
| 179 | cubuk | 1 |
| 180 | cysto-urographic | 1 |
| 181 | d-first | 1 |
| 182 | ddi/ddc | 1 |
| 183 | design-type | 1 |
| 184 | diabcare-asia | 1 |
| 185 | dose-finding/dose-confirming | 1 |
| 186 | dublin-based | 1 |
| 187 | eight-country | 1 |
| 188 | electroencephalographer-blinded | 1 |
| 189 | entry-into-human | 1 |
| 190 | estimates.one | 1 |
| 191 | fats-observational | 1 |
| 192 | feasibility-pilot | 1 |
| 193 | first-in-many | 1 |
| 194 | first-in-pediatrics | 1 |
| 195 | focus3 | 1 |
| 196 | geane | 1 |
| 197 | gissi-prevention | 1 |
| 198 | guidelines.the | 1 |
| 199 | hc02 | 1 |
| 200 | hd2000-gisl | 1 |
| 201 | helpline-based | 1 |
| 202 | hipaa-compatible | 1 |
| 203 | histogerd | 1 |
| 204 | hivis-03 | 1 |
| 205 | hydration-controlled | 1 |
| 206 | hypro | 1 |
| 207 | i91-0001 | 1 |
| 208 | iacuc-approved | 1 |
| 209 | imaging-blinded | 1 |
| 210 | industrial-based | 1 |
| 211 | interventionone | 1 |
| 212 | intubation.this | 1 |
| 213 | investigator-academic-driven | 1 |
| 214 | iphiwwe | 1 |
| 215 | isrctn-registered | 1 |
| 216 | knowledge-translation-based | 1 |
| 217 | l99-15 | 1 |
| 218 | l991 | 1 |
| 219 | limited-sized | 1 |
| 220 | lnh87-lnh93 | 1 |
| 221 | locally-derived | 1 |
| 222 | logic-1 | 1 |
| 223 | ma-treatment | 1 |
| 224 | magic-b | 1 |
| 225 | magnifiers.one | 1 |
| 226 | maintenance-of-effect | 1 |
| 227 | markers.this | 1 |
| 228 | medicine/endocrinology | 1 |
| 229 | method-developing | 1 |
| 230 | mi-plus | 1 |
| 231 | mother-to-child-prevention | 1 |
| 232 | mra-based | 1 |
| 233 | multi-institutions | 1 |
| 234 | multi-worksite-based | 1 |
| 235 | multimillion-dollar | 1 |
| 236 | multination | 1 |
| 237 | nej001 | 1 |
| 238 | nifedipine/metoprolol | 1 |
| 239 | nih/nida-funded | 1 |
| 240 | non-prospective | 1 |
| 241 | nutri-metabolomics | 1 |
| 242 | observation-randomized | 1 |
| 243 | one-practice | 1 |
| 244 | open-road | 1 |
| 245 | optical-raman-spectroscopy | 1 |
| 246 | outcome.this | 1 |
| 247 | p-medicine | 1 |
| 248 | p1056 | 1 |
| 249 | pacing-hemodynamic | 1 |
| 250 | paired-cohort | 1 |
| 251 | patient-anesthesiologist-blinded | 1 |
| 252 | perspective.the | 1 |
| 253 | pet-boost | 1 |
| 254 | pharmaco-clinical | 1 |
| 255 | phase-4 | 1 |
| 256 | phfmri | 1 |
| 257 | pi-switch | 1 |
| 258 | pilot-controlled | 1 |
| 259 | pilot-evaluation | 1 |
| 260 | polit | 1 |
| 261 | pospective | 1 |
| 262 | pre-/postpilot | 1 |
| 263 | pre-pregnancynormal | 1 |
| 264 | preford | 1 |
| 265 | problem-solved | 1 |
| 266 | quality-enhancement | 1 |
| 267 | question.the | 1 |
| 268 | randomized-prospective | 1 |
| 269 | randomizied | 1 |
| 270 | rate-of-growth | 1 |
| 271 | rave-population | 1 |
| 272 | reperfusion/occlusion-2 | 1 |
| 273 | replication-discovery | 1 |
| 274 | retro-prospective | 1 |
| 275 | reversal-phase | 1 |
| 276 | review.two | 1 |
| 277 | s9921 | 1 |
| 278 | screening-intervention | 1 |
| 279 | selection-design | 1 |
| 280 | semi-replicative | 1 |
| 281 | sexpulse | 1 |
| 282 | sidem | 1 |
| 283 | signal-finding | 1 |
| 284 | single-rater-blinded | 1 |
| 285 | size.no | 1 |
| 286 | sizes.the | 1 |
| 287 | sodis-promotion | 1 |
| 288 | space-2 | 1 |
| 289 | steady-flow | 1 |
| 290 | study-i | 1 |
| 291 | study.primary | 1 |
| 292 | symplicity-htn-2 | 1 |
| 293 | syndromes.this | 1 |
| 294 | systems-biology-based | 1 |
| 295 | termprom | 1 |
| 296 | test-4 | 1 |
| 297 | therapy-optimization | 1 |
| 298 | therapy.to | 1 |
| 299 | thorough-qt | 1 |
| 300 | three-night | 1 |
| 301 | three-study | 1 |
| 302 | treatment.main | 1 |
| 303 | trial/cohort | 1 |
| 304 | trials.interventional | 1 |
| 305 | trials.this | 1 |
| 306 | trials/nederlands | 1 |
| 307 | two-experiment | 1 |
| 308 | two-institution | 1 |
| 309 | two-patient | 1 |
| 310 | ukallxi | 1 |
| 311 | usual.main | 1 |
| 312 | usual.this | 1 |
| 313 | venetia | 1 |
| 314 | viviane | 1 |
| 315 | wt9101 | 1 |
| 316 | xviii/aio | 1 |
| 1 | -asia | 1 |
| 2 | -bio | 1 |
| 3 | -netherlands | 1 |
| 4 | -p1b | 1 |
| 5 | -potsdam | 2 |
| 6 | 0104 | 1 |
| 7 | 0110 | 1 |
| 8 | 0110/ml22011 | 1 |
| 9 | 0501 | 2 |
| 10 | 0537 | 1 |
| 11 | 08-06 | 1 |
| 12 | 08062 | 1 |
| 13 | 08983 | 1 |
| 14 | 10981-22023 | 3 |
| 15 | 12-week-long | 3 |
| 16 | 12174 | 2 |
| 17 | 14,500-patient | 1 |
| 18 | 2000-1 | 1 |
| 19 | 2005-01 | 7 |
| 20 | 22881-10882 | 2 |
| 21 | 243,400 | 1 |
| 22 | 24954 | 3 |
| 23 | 3,000-patient | 1 |
| 24 | 35-week | 3 |
| 25 | 38-week | 8 |
| 26 | 4-country | 2 |
| 27 | 53-week | 2 |
| 28 | 55971 | 4 |
| 29 | 6-month-treatment | 1 |
| 30 | 60-patient | 6 |
| 31 | 62961 | 1 |
| 32 | 70-compound | 1 |
| 33 | 8801 | 1 |
| 34 | 8week | 1 |
| 35 | 9-site | 1 |
| 36 | 94-17 | 1 |
| 37 | 95-06 | 1 |
| 38 | 97-d | 2 |
| 39 | a1chieve® | 1 |
| 40 | a5164 | 3 |
| 41 | actrn12612000889853the | 1 |
| 42 | ademex | 13 |
| 43 | agents.this | 1 |
| 44 | ago-1 | 1 |
| 45 | alcohol-challenge | 1 |
| 46 | allene-involved | 1 |
| 47 | anahydret | 2 |
| 48 | analytical-descriptive | 1 |
| 49 | anglo-danish-dutch | 8 |
| 50 | anti-atheroma | 3 |
| 51 | anti-dabetic | 1 |
| 52 | artico | 2 |
| 53 | artscan | 4 |
| 54 | atmi | 2 |
| 55 | b-30 | 1 |
| 56 | backpassage | 2 |
| 57 | barmer | 2 |
| 58 | before-after | 170 |
| 59 | before-and-after | 124 |
| 60 | bfr14 | 5 |
| 61 | bifactorial | 1 |
| 62 | blind-rater | 1 |
| 63 | bora | 6 |
| 64 | bronchoscopy.the | 1 |
| 65 | bupropian | 1 |
| 66 | c-07 | 8 |
| 67 | cairo2 | 14 |
| 68 | calisto | 2 |
| 69 | capp1 | 2 |
| 70 | capp2 | 5 |
| 71 | caress-in-ami | 2 |
| 72 | ce.3 | 4 |
| 73 | cftr-modulator | 1 |
| 74 | charon | 1 |
| 75 | chemistry-focused | 1 |
| 76 | chewfree | 3 |
| 77 | clinical-experimental | 2 |
| 78 | clinicoepidemiologic | 1 |
| 79 | cll4b | 1 |
| 80 | co.17 | 3 |
| 81 | combi-d | 2 |
| 82 | community-screening | 2 |
| 83 | competence-focused | 1 |
| 84 | condition.this | 2 |
| 85 | consort-compliant | 4 |
| 86 | corea-taxus | 2 |
| 87 | criteria-2 | 1 |
| 88 | criteria.one | 2 |
| 89 | criteria.this | 1 |
| 90 | criteria.two | 1 |
| 91 | criteriathe | 1 |
| 92 | crossover-randomized | 1 |
| 93 | cubuk | 1 |
| 94 | cysto-urographic | 1 |
| 95 | d-first | 1 |
| 96 | ddi/ddc | 1 |
| 97 | debiut | 2 |
| 98 | design-type | 1 |
| 99 | diabcare-asia | 1 |
| 100 | dose-finding/dose-confirming | 1 |
| 101 | dream3 | 2 |
| 102 | dublin-based | 1 |
| 103 | eight-country | 1 |
| 104 | electroencephalographer-blinded | 1 |
| 105 | entry-into-human | 1 |
| 106 | estimates.one | 1 |
| 107 | euphas | 9 |
| 108 | european/canadian | 3 |
| 109 | exploratory/descriptive | 2 |
| 110 | falldem | 3 |
| 111 | fats-observational | 1 |
| 112 | feasibility-pilot | 1 |
| 113 | fiat | 4 |
| 114 | firis | 3 |
| 115 | first-in-human | 137 |
| 116 | first-in-humans | 7 |
| 117 | first-in-man | 88 |
| 118 | first-in-many | 1 |
| 119 | first-in-patient | 4 |
| 120 | first-in-pediatrics | 1 |
| 121 | first-time-in-human | 9 |
| 122 | fixed-sample | 12 |
| 123 | focus3 | 1 |
| 124 | follow-on | 61 |
| 125 | follow-up.one | 3 |
| 126 | food-effect | 13 |
| 127 | fruit-juice | 8 |
| 128 | full-scale | 221 |
| 129 | geane | 1 |
| 130 | geparsixto | 4 |
| 131 | gepartrio | 13 |
| 132 | gissi-af | 9 |
| 133 | gissi-prevention | 1 |
| 134 | glucontrol | 2 |
| 135 | glycogen-depletion | 2 |
| 136 | group-comparison | 2 |
| 137 | group.one | 7 |
| 138 | guidage | 9 |
| 139 | guidelines.the | 1 |
| 140 | hc02 | 1 |
| 141 | hd2000-gisl | 1 |
| 142 | hebe | 10 |
| 143 | helena | 5 |
| 144 | helpline-based | 1 |
| 145 | hipaa-compatible | 1 |
| 146 | hipaa-compliant | 22 |
| 147 | histogerd | 1 |
| 148 | hivis-03 | 1 |
| 149 | hoorn | 9 |
| 150 | husoft | 3 |
| 151 | hydration-controlled | 1 |
| 152 | hypothesis-generation | 3 |
| 153 | hypro | 1 |
| 154 | i91-0001 | 1 |
| 155 | iacuc-approved | 1 |
| 156 | imaging-blinded | 1 |
| 157 | implementation-effectiveness | 2 |
| 158 | in-human | 6 |
| 159 | industrial-based | 1 |
| 160 | interventionone | 1 |
| 161 | intubation.this | 1 |
| 162 | investigator-academic-driven | 1 |
| 163 | ionia-e | 5 |
| 164 | iphiwwe | 1 |
| 165 | isrctn-registered | 1 |
| 166 | knowledge-translation-based | 1 |
| 167 | l99-15 | 1 |
| 168 | l991 | 1 |
| 169 | limited-sized | 1 |
| 170 | lnh87-lnh93 | 1 |
| 171 | locally-derived | 1 |
| 172 | logic-1 | 1 |
| 173 | ma-treatment | 1 |
| 174 | magic-b | 1 |
| 175 | magnifiers.one | 1 |
| 176 | maintenance-of-effect | 1 |
| 177 | manikin-based | 2 |
| 178 | markers.this | 1 |
| 179 | medicine/endocrinology | 1 |
| 180 | meta-analysis.one | 3 |
| 181 | method-developing | 1 |
| 182 | mi-plus | 1 |
| 183 | mm-bo2005 | 2 |
| 184 | modest-sized | 4 |
| 185 | more-care | 2 |
| 186 | mother-to-child-prevention | 1 |
| 187 | mra-based | 1 |
| 188 | multi-cohort | 4 |
| 189 | multi-institutions | 1 |
| 190 | multi-rater | 2 |
| 191 | multi-worksite-based | 1 |
| 192 | multi-year | 11 |
| 193 | multimillion-dollar | 1 |
| 194 | multination | 1 |
| 195 | multiple-case | 6 |
| 196 | nej001 | 1 |
| 197 | nifedipine/metoprolol | 1 |
| 198 | nih/nida-funded | 1 |
| 199 | non-prospective | 1 |
| 200 | nutri-metabolomics | 1 |
| 201 | observation-randomized | 1 |
| 202 | omegad | 5 |
| 203 | one-practice | 1 |
| 204 | open-road | 1 |
| 205 | opptimum | 2 |
| 206 | opt-tms | 5 |
| 207 | optical-raman-spectroscopy | 1 |
| 208 | outcome.this | 1 |
| 209 | p-medicine | 1 |
| 210 | p1056 | 1 |
| 211 | pacing-hemodynamic | 1 |
| 212 | pacome | 3 |
| 213 | paired-cohort | 1 |
| 214 | pan-asia | 6 |
| 215 | patient-anesthesiologist-blinded | 1 |
| 216 | perspective.the | 1 |
| 217 | pet-boost | 1 |
| 218 | ph2a | 2 |
| 219 | pharmaco-clinical | 1 |
| 220 | pharmacoimaging | 3 |
| 221 | phase-4 | 1 |
| 222 | phfmri | 1 |
| 223 | pi-switch | 1 |
| 224 | piilr | 2 |
| 225 | pilot | 6,580 |
| 226 | pilot-controlled | 1 |
| 227 | pilot-evaluation | 1 |
| 228 | pilot/feasibility | 8 |
| 229 | polit | 1 |
| 230 | pospective | 1 |
| 231 | postregistration | 3 |
| 232 | pre-/postpilot | 1 |
| 233 | pre-point | 4 |
| 234 | pre-pregnancynormal | 1 |
| 235 | prefher | 7 |
| 236 | preford | 1 |
| 237 | preintervention-postintervention | 4 |
| 238 | problem-solved | 1 |
| 239 | process-improvement | 2 |
| 240 | proof-of-concept | 355 |
| 241 | proof-of-mechanism | 2 |
| 242 | proof-of-principle | 89 |
| 243 | quality-enhancement | 1 |
| 244 | question.the | 1 |
| 245 | randomized-prospective | 1 |
| 246 | randomizied | 1 |
| 247 | rate-of-growth | 1 |
| 248 | rave-population | 1 |
| 249 | regenerate-ihd | 3 |
| 250 | registry-type | 3 |
| 251 | reperfusion/occlusion-2 | 1 |
| 252 | replication-discovery | 1 |
| 253 | retro-prospective | 1 |
| 254 | reversal-phase | 1 |
| 255 | review.six | 2 |
| 256 | review.two | 1 |
| 257 | ricover | 2 |
| 258 | romio | 5 |
| 259 | s9921 | 1 |
| 260 | scorpius | 3 |
| 261 | screening-intervention | 1 |
| 262 | selection-design | 1 |
| 263 | semi-replicative | 1 |
| 264 | sertraline-controlled | 2 |
| 265 | setting.the | 3 |
| 266 | sexpulse | 1 |
| 267 | shiva | 4 |
| 268 | sidem | 1 |
| 269 | signal-finding | 1 |
| 270 | signal-searching | 4 |
| 271 | single-ascending-dose | 12 |
| 272 | single-rater-blinded | 1 |
| 273 | size.no | 1 |
| 274 | sizes.the | 1 |
| 275 | smile-4 | 3 |
| 276 | sodis-promotion | 1 |
| 277 | space-2 | 1 |
| 278 | split-lesion | 2 |
| 279 | steady-flow | 1 |
| 280 | strike-through | 2 |
| 281 | study-i | 1 |
| 282 | study.primary | 1 |
| 283 | symplicity-htn-2 | 1 |
| 284 | syncan | 2 |
| 285 | syndromes.this | 1 |
| 286 | systems-biology-based | 1 |
| 287 | termprom | 1 |
| 288 | test-4 | 1 |
| 289 | thalassa | 6 |
| 290 | therapy-optimization | 1 |
| 291 | therapy.to | 1 |
| 292 | thorough-qt | 1 |
| 293 | three-night | 1 |
| 294 | three-pronged | 7 |
| 295 | three-study | 1 |
| 296 | treatment.main | 1 |
| 297 | trial.the | 6 |
| 298 | trial/cohort | 1 |
| 299 | trialnet | 6 |
| 300 | trials.interventional | 1 |
| 301 | trials.one | 5 |
| 302 | trials.this | 1 |
| 303 | trials/controlled | 14 |
| 304 | trials/nederlands | 1 |
| 305 | ttm-based | 4 |
| 306 | two-experiment | 1 |
| 307 | two-institution | 1 |
| 308 | two-patient | 1 |
| 309 | ukallxi | 1 |
| 310 | usual.main | 1 |
| 311 | usual.this | 1 |
| 312 | vanguard | 34 |
| 313 | venetia | 1 |
| 314 | viviane | 1 |
| 315 | wt9101 | 1 |
| 316 | xviii/aio | 1 |
| 1 | 243,400 | 1 |
| 2 | 0110 | 1 |
| 3 | b-30 | 1 |
| 4 | 2000-1 | 1 |
| 5 | logic-1 | 1 |
| 6 | ago-1 | 1 |
| 7 | 2005-01 | 7 |
| 8 | i91-0001 | 1 |
| 9 | nej001 | 1 |
| 10 | wt9101 | 1 |
| 11 | 0501 | 2 |
| 12 | 8801 | 1 |
| 13 | 0110/ml22011 | 1 |
| 14 | s9921 | 1 |
| 15 | 62961 | 1 |
| 16 | 55971 | 4 |
| 17 | l991 | 1 |
| 18 | capp1 | 2 |
| 19 | criteria-2 | 1 |
| 20 | space-2 | 1 |
| 21 | reperfusion/occlusion-2 | 1 |
| 22 | symplicity-htn-2 | 1 |
| 23 | hc02 | 1 |
| 24 | 08062 | 1 |
| 25 | 22881-10882 | 2 |
| 26 | cairo2 | 14 |
| 27 | capp2 | 5 |
| 28 | ce.3 | 4 |
| 29 | hivis-03 | 1 |
| 30 | 10981-22023 | 3 |
| 31 | 08983 | 1 |
| 32 | lnh87-lnh93 | 1 |
| 33 | dream3 | 2 |
| 34 | focus3 | 1 |
| 35 | smile-4 | 3 |
| 36 | phase-4 | 1 |
| 37 | test-4 | 1 |
| 38 | 0104 | 1 |
| 39 | bfr14 | 5 |
| 40 | 24954 | 3 |
| 41 | a5164 | 3 |
| 42 | 12174 | 2 |
| 43 | mm-bo2005 | 2 |
| 44 | l99-15 | 1 |
| 45 | 95-06 | 1 |
| 46 | 08-06 | 1 |
| 47 | p1056 | 1 |
| 48 | c-07 | 8 |
| 49 | 94-17 | 1 |
| 50 | co.17 | 3 |
| 51 | 0537 | 1 |
| 52 | ph2a | 2 |
| 53 | -asia | 1 |
| 54 | diabcare-asia | 1 |
| 55 | pan-asia | 6 |
| 56 | venetia | 1 |
| 57 | anti-atheroma | 3 |
| 58 | helena | 5 |
| 59 | bora | 6 |
| 60 | thalassa | 6 |
| 61 | shiva | 4 |
| 62 | magic-b | 1 |
| 63 | -p1b | 1 |
| 64 | cll4b | 1 |
| 65 | ddi/ddc | 1 |
| 66 | clinicoepidemiologic | 1 |
| 67 | cysto-urographic | 1 |
| 68 | pacing-hemodynamic | 1 |
| 69 | anti-dabetic | 1 |
| 70 | 97-d | 2 |
| 71 | combi-d | 2 |
| 72 | omegad | 5 |
| 73 | open-road | 1 |
| 74 | imaging-blinded | 1 |
| 75 | electroencephalographer-blinded | 1 |
| 76 | single-rater-blinded | 1 |
| 77 | patient-anesthesiologist-blinded | 1 |
| 78 | nih/nida-funded | 1 |
| 79 | three-pronged | 7 |
| 80 | randomizied | 1 |
| 81 | sertraline-controlled | 2 |
| 82 | hydration-controlled | 1 |
| 83 | pilot-controlled | 1 |
| 84 | trials/controlled | 14 |
| 85 | isrctn-registered | 1 |
| 86 | mra-based | 1 |
| 87 | helpline-based | 1 |
| 88 | multi-worksite-based | 1 |
| 89 | industrial-based | 1 |
| 90 | ttm-based | 4 |
| 91 | manikin-based | 2 |
| 92 | dublin-based | 1 |
| 93 | knowledge-translation-based | 1 |
| 94 | systems-biology-based | 1 |
| 95 | competence-focused | 1 |
| 96 | chemistry-focused | 1 |
| 97 | locally-derived | 1 |
| 98 | problem-solved | 1 |
| 99 | allene-involved | 1 |
| 100 | iacuc-approved | 1 |
| 101 | observation-randomized | 1 |
| 102 | crossover-randomized | 1 |
| 103 | limited-sized | 1 |
| 104 | modest-sized | 4 |
| 105 | regenerate-ihd | 3 |
| 106 | 70-compound | 1 |
| 107 | vanguard | 34 |
| 108 | histogerd | 1 |
| 109 | preford | 1 |
| 110 | ionia-e | 5 |
| 111 | hebe | 10 |
| 112 | one-practice | 1 |
| 113 | fruit-juice | 8 |
| 114 | chewfree | 3 |
| 115 | guidage | 9 |
| 116 | backpassage | 2 |
| 117 | alcohol-challenge | 1 |
| 118 | perspective.the | 1 |
| 119 | setting.the | 3 |
| 120 | trial.the | 6 |
| 121 | question.the | 1 |
| 122 | guidelines.the | 1 |
| 123 | sizes.the | 1 |
| 124 | bronchoscopy.the | 1 |
| 125 | actrn12612000889853the | 1 |
| 126 | criteriathe | 1 |
| 127 | full-scale | 221 |
| 128 | hipaa-compatible | 1 |
| 129 | proof-of-principle | 89 |
| 130 | fixed-sample | 12 |
| 131 | pacome | 3 |
| 132 | geane | 1 |
| 133 | viviane | 1 |
| 134 | p-medicine | 1 |
| 135 | criteria.one | 2 |
| 136 | follow-up.one | 3 |
| 137 | group.one | 7 |
| 138 | estimates.one | 1 |
| 139 | meta-analysis.one | 3 |
| 140 | trials.one | 5 |
| 141 | magnifiers.one | 1 |
| 142 | interventionone | 1 |
| 143 | design-type | 1 |
| 144 | registry-type | 3 |
| 145 | more-care | 2 |
| 146 | multiple-case | 6 |
| 147 | reversal-phase | 1 |
| 148 | sexpulse | 1 |
| 149 | single-ascending-dose | 12 |
| 150 | 9-site | 1 |
| 151 | semi-replicative | 1 |
| 152 | pospective | 1 |
| 153 | randomized-prospective | 1 |
| 154 | non-prospective | 1 |
| 155 | retro-prospective | 1 |
| 156 | analytical-descriptive | 1 |
| 157 | exploratory/descriptive | 2 |
| 158 | iphiwwe | 1 |
| 159 | gissi-af | 9 |
| 160 | signal-finding | 1 |
| 161 | pharmacoimaging | 3 |
| 162 | signal-searching | 4 |
| 163 | dose-finding/dose-confirming | 1 |
| 164 | community-screening | 2 |
| 165 | method-developing | 1 |
| 166 | 12-week-long | 3 |
| 167 | pi-switch | 1 |
| 168 | anglo-danish-dutch | 8 |
| 169 | strike-through | 2 |
| 170 | rate-of-growth | 1 |
| 171 | study-i | 1 |
| 172 | caress-in-ami | 2 |
| 173 | atmi | 2 |
| 174 | phfmri | 1 |
| 175 | ukallxi | 1 |
| 176 | 53-week | 2 |
| 177 | 35-week | 3 |
| 178 | 38-week | 8 |
| 179 | 8week | 1 |
| 180 | cubuk | 1 |
| 181 | pharmaco-clinical | 1 |
| 182 | bifactorial | 1 |
| 183 | pre-pregnancynormal | 1 |
| 184 | fats-observational | 1 |
| 185 | trials.interventional | 1 |
| 186 | clinical-experimental | 2 |
| 187 | nifedipine/metoprolol | 1 |
| 188 | glucontrol | 2 |
| 189 | hd2000-gisl | 1 |
| 190 | -potsdam | 2 |
| 191 | sidem | 1 |
| 192 | falldem | 3 |
| 193 | termprom | 1 |
| 194 | proof-of-mechanism | 2 |
| 195 | opptimum | 2 |
| 196 | syncan | 2 |
| 197 | artscan | 4 |
| 198 | european/canadian | 3 |
| 199 | bupropian | 1 |
| 200 | first-in-man | 88 |
| 201 | in-human | 6 |
| 202 | first-time-in-human | 9 |
| 203 | first-in-human | 137 |
| 204 | entry-into-human | 1 |
| 205 | investigator-academic-driven | 1 |
| 206 | selection-design | 1 |
| 207 | usual.main | 1 |
| 208 | treatment.main | 1 |
| 209 | follow-on | 61 |
| 210 | split-lesion | 2 |
| 211 | rave-population | 1 |
| 212 | multination | 1 |
| 213 | hypothesis-generation | 3 |
| 214 | postregistration | 3 |
| 215 | pilot-evaluation | 1 |
| 216 | therapy-optimization | 1 |
| 217 | glycogen-depletion | 2 |
| 218 | mother-to-child-prevention | 1 |
| 219 | gissi-prevention | 1 |
| 220 | screening-intervention | 1 |
| 221 | preintervention-postintervention | 4 |
| 222 | sodis-promotion | 1 |
| 223 | two-institution | 1 |
| 224 | charon | 1 |
| 225 | group-comparison | 2 |
| 226 | hoorn | 9 |
| 227 | artico | 2 |
| 228 | xviii/aio | 1 |
| 229 | -bio | 1 |
| 230 | romio | 5 |
| 231 | gepartrio | 13 |
| 232 | size.no | 1 |
| 233 | hypro | 1 |
| 234 | therapy.to | 1 |
| 235 | calisto | 2 |
| 236 | geparsixto | 4 |
| 237 | criteria.two | 1 |
| 238 | review.two | 1 |
| 239 | multi-year | 11 |
| 240 | multimillion-dollar | 1 |
| 241 | prefher | 7 |
| 242 | barmer | 2 |
| 243 | blind-rater | 1 |
| 244 | multi-rater | 2 |
| 245 | before-and-after | 124 |
| 246 | before-after | 170 |
| 247 | ricover | 2 |
| 248 | piilr | 2 |
| 249 | cftr-modulator | 1 |
| 250 | euphas | 9 |
| 251 | nutri-metabolomics | 1 |
| 252 | first-in-pediatrics | 1 |
| 253 | trials/nederlands | 1 |
| 254 | -netherlands | 1 |
| 255 | criteria.this | 1 |
| 256 | outcome.this | 1 |
| 257 | usual.this | 1 |
| 258 | intubation.this | 1 |
| 259 | condition.this | 2 |
| 260 | syndromes.this | 1 |
| 261 | trials.this | 1 |
| 262 | markers.this | 1 |
| 263 | agents.this | 1 |
| 264 | firis | 3 |
| 265 | opt-tms | 5 |
| 266 | first-in-humans | 7 |
| 267 | multi-institutions | 1 |
| 268 | implementation-effectiveness | 2 |
| 269 | scorpius | 3 |
| 270 | mi-plus | 1 |
| 271 | corea-taxus | 2 |
| 272 | fiat | 4 |
| 273 | food-effect | 13 |
| 274 | maintenance-of-effect | 1 |
| 275 | trialnet | 6 |
| 276 | anahydret | 2 |
| 277 | husoft | 3 |
| 278 | three-night | 1 |
| 279 | polit | 1 |
| 280 | hipaa-compliant | 22 |
| 281 | consort-compliant | 4 |
| 282 | 3,000-patient | 1 |
| 283 | 14,500-patient | 1 |
| 284 | 60-patient | 6 |
| 285 | first-in-patient | 4 |
| 286 | two-patient | 1 |
| 287 | quality-enhancement | 1 |
| 288 | process-improvement | 2 |
| 289 | two-experiment | 1 |
| 290 | ma-treatment | 1 |
| 291 | 6-month-treatment | 1 |
| 292 | pre-point | 4 |
| 293 | pilot | 6,580 |
| 294 | feasibility-pilot | 1 |
| 295 | pre-/postpilot | 1 |
| 296 | proof-of-concept | 355 |
| 297 | thorough-qt | 1 |
| 298 | paired-cohort | 1 |
| 299 | multi-cohort | 4 |
| 300 | trial/cohort | 1 |
| 301 | pet-boost | 1 |
| 302 | d-first | 1 |
| 303 | debiut | 2 |
| 304 | steady-flow | 1 |
| 305 | ademex | 13 |
| 306 | review.six | 2 |
| 307 | three-study | 1 |
| 308 | medicine/endocrinology | 1 |
| 309 | first-in-many | 1 |
| 310 | optical-raman-spectroscopy | 1 |
| 311 | study.primary | 1 |
| 312 | replication-discovery | 1 |
| 313 | 4-country | 2 |
| 314 | eight-country | 1 |
| 315 | pilot/feasibility | 8 |
| 316 | a1chieve® | 1 |